{"product_id":"multidisciplinary-head-and-neck-cancers-symposium-2022","title":"Multidisciplinary Head and Neck Cancers Symposium 2022","description":"\u003cdiv class=\"ContentUserControl\"\u003e\n\u003cdiv class=\"row event-dates\"\u003e\n\u003cdiv\u003eMultidisciplinary Head and Neck Cancers Symposium 2022 The 2022 Multidisciplinary Head and Neck Cancers Symposium will take place February 24-26, 2022, in Phoenix, Arizona. This practical and interactive meeting is for the entire head and neck cancer care community. The program will provide the most up-to-date information on multidisciplinary therapies, the latest clinical research, new treatment strategies, supportive care, scientific breakthroughs and toxicity mitigation.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cul\u003e\n\u003cli class=\"col-md-12\"\u003e\n\u003ch3\u003e\n\u003cspan class=\"text-muted\" id=\"MainCopy_ctl05_EventWhenSpan\"\u003eWhen:  \u003c\/span\u003eFeb 24, 2022\u003c\/h3\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"ContentItemMVC\"\u003e\n\u003cdiv class=\"MVCContent\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"ContentUserControl\"\u003e\n\u003cdiv id=\"MainCopy_ctl08_DescriptionSection\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"col-md-10\"\u003e\n\u003cem\u003ePresented by American Head \u0026amp; Neck Society, American Society of Clinical Oncology, American Society for Radiation Oncology and the Society for Immunotherapy of Cancer\u003c\/em\u003e\n\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cstrong\u003e+ Target Audience: medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists\/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAgenda.pdf\u003c\/li\u003e\n\u003cli\u003eThursday, February 24, 2022 Part 1.mp4\u003c\/li\u003e\n\u003cli\u003eThursday, February 24, 2022 Part 2.mp4\u003c\/li\u003e\n\u003cli\u003eFriday, February 25, 2022 Part 1.mp4\u003c\/li\u003e\n\u003cli\u003eFriday, February 25, 2022 Part 2.mp4\u003c\/li\u003e\n\u003cli\u003eSaturday, February 26, 2022.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e* Detail:\u003cbr\u003e\u003ch3 class=\"microAccordianHeader active\"\u003eWednesday, February 23, 2022\u003c\/h3\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"micro_accbod\" id=\"microAccordianBody_ScheduleofEvents1\"\u003e\n\u003cdiv class=\"ben_tableStyles\"\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"25%\"\u003e4:00 p.m. – 6:00 p.m.\u003c\/td\u003e\n\u003ctd width=\"100%\"\u003e\u003cstrong\u003eRegistration Open\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbr\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"microAccordianHeader active\"\u003eThursday, February 24, 2022\u003c\/div\u003e\n\u003cdiv class=\"micro_accbod\" id=\"microAccordianBody_ScheduleofEvents2\"\u003e\n\u003cdiv class=\"ben_tableStyles\"\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"25%\"\u003e7:00 a.m. – 4:30 p.m.\u003c\/td\u003e\n\u003ctd width=\"75%\"\u003e\u003cstrong\u003eRegistration Open\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:00 a.m. – 8:00 a.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eContinental Breakfast\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:50 a.m. – 8:00 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDay One Welcome\u003c\/strong\u003e\u003cbr\u003eCherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:00 a.m. – 8:20 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePatient Perspective: Building a Community of HNL Patients, Coaches and Mentors\u003c\/strong\u003e\u003cbr\u003eSpeaker: Michael West\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:20 a.m. – 9:50\u003cstrong\u003e \u003c\/strong\u003ea.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePatient-centric Head and Neck Care \u003c\/strong\u003e\u003cbr\u003eModerator: Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComprehensive Rehabilitation of the Head and Neck Patient\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eHeather Starmer, MA, CCC-SLP, BCS-S, Stanford University, Stanford, California \u003cstrong\u003e[SLP]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOral\/Dental Needs in HNC Survivors\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eJoel Epstein, DMD, MSD, Cedars-Sinai, Los Angeles \u003cb\u003e[OMFS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAddressing the Psychological Aspects of Head and Neck Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eElizabeth Cash, PhD, University of Louisville, Louisville, Kentucky\u003cstrong\u003e [Psychologist\u003c\/strong\u003e\u003cstrong\u003e]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe Artistry of Facial Prosthetics\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDevin Okay, DDS, Mount Sinai Hospital, New York \u003cstrong\u003e[\u003c\/strong\u003e\u003cstrong\u003eOMFS]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNutrition in Head and Neck Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003ePatricia Rubio, MBA, MS, University of California, San Diego \u003cstrong\u003e[Nutritionist]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuestions and Answers\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:50 a.m. – 10:35 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cb\u003eKeynote I: Disparities in Head and Neck Cancer\u003c\/b\u003e\u003cbr\u003eModerator: Dan Zandberg, MD, University of Pittsburgh Medical Center, Pittsburgh \u003cb\u003e[M]\u003c\/b\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eSharon Spencer, MD, University of Alabama at Birmingham, Birmingham, Alabama\u003cstrong\u003e [R]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCharles Moore, MD, Emory University, Atlanta \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:35 a.m. – 11:00 a.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCoffee Break\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:00 a.m. – 12:30 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eEscalation Strategies and Novel Approaches in Locally Advanced Head and Neck Cancer\u003c\/strong\u003e\u003cbr\u003eModerator: Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunotherapy in the Curative Intent Setting\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eSana Karam, MD, PhD, University of Colorado, Denver\u003cstrong\u003e [R]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe Role of Preop IO in Locally Advanced HNC\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eRavi Uppaluri, MD, PhD, Brigham and Women’s Hospital, Boston\u003cstrong\u003e [HNS]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNovel Radiosensitizers\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eHeath Skinner, MD, PhD, University of Pittsburgh,  Pittsburgh \u003cstrong\u003e[R]\u003c\/strong\u003e​\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNasopharynx: Induction vs Adjuvant – Where do we go from here?\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDimitrios Colevas, MD, Stanford University, Stanford, California \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuestions and Answers\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12:30 p.m. – 1:30 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eLunch in the Exhibit Hall\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eEarly-career and Trainee Networking Luncheon: Choosing Your Career Path\u003c\/strong\u003e\u003cbr\u003eHighlight careers briefly at the beginning and then break out into small groups at the different round tables.\u003cbr\u003eModerator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eJulie Bauman, MD, MPH, University of Arizona, Tucson, Arizona \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eKatherine Hutcheson, PhD, MD Anderson Cancer Center, Houston \u003cstrong\u003e[Speech Path]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFaye Johnson, MD, PhD, MD Anderson Cancer Center, Houston \u003cb\u003e[M]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003cli\u003eLoren Mell, MD, University of California, San Diego \u003cstrong\u003e[R]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMaie St. John, MD, PhD, UCLA David Geffen, Los Angeles \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1:30 p.m. – 3:00 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eK. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session\u003c\/strong\u003e\u003cbr\u003eModerator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEarly Toxicity and Patient Reported Outcomes from a Phase 2 Trial of FDG-PET Response-based De-escalated Definitive Radiotherapy for p16+ Oropharynx Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eSteven Allen, University of Michigan, Ann Arbor, Michigan\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNon-inferiority Margin and Nodal Analysis of De-escalated Adjuvant Radiation Therapy (DART) for HPV-related Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Preplanned Pooled Analysis of MC1273 \u0026amp; MC1675\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDaniel Ma, Mayo Clinic, Rochester, Minnesota\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDetection of Occult Recurrence Using Circulating HPV Tumor DNA among Patients Treated for HPV-driven Oropharyngeal Squamous Cell Carcinoma\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eGlenn Hanna, Dana-Farber Cancer Institute, Harvard Medical School, Boston\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKinetics of Circulating Human Papillomavirus (cHPV) DNA in Plasma and Oral Gargles from Patients with HPV-positive Oropharyngeal Cancer (OPC) Treated with Definitive Radiation Therapy\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMichelle Echevarria, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eA Clinically Translatable, Extensively Validated Immune-based Classification of Human Papillomavirus-associated Head and Neck Cancer with Implications for Treatment Deintensification and Immunotherapy\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003ePeter Zeng, Western University, London, Ontario, Canada\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePredicted Th2 Infiltrate is Associated with Outcome in HPV(-) Head and Neck Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMohamed Abdelhakiem, UPMC Hillman Cancer Center, Pittsburgh\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLoss of HPV 16- E2 Predicts Disease Free Survival and Promotes Platinum Resistance in Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMolly Heft-Neal, University of Michigan, Ann Arbor, Michigan\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeoadjuvant Immunoradiotherapy in a Tobacco-Signature Preclinical Oral Squamous Cell Carcinoma Model\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eRobert Saddawi-Konefka, University of California, San Diego\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHPV E5 Mediates Resistance to PD-1 Checkpoint Blockade via Inhibition of MHC and IFN Pathway\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAndrew Sharabi, University of California, San Diego\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:00 p.m. – 3:30 p.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCoffee Break\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:30 p.m. – 4:30 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCase Study and Debate: Curative Intent in Elderly and Frail\u003c\/strong\u003e\u003cbr\u003eModerator: Zain Husain, MD, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada\u003cstrong\u003e [R]\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eSusan McCammon, MD, University of Alabama, Birmingham, Birmingham, Alabama \u003cstrong\u003e[HNS]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eLoren Mell, MD, University of California, San Diego \u003cstrong\u003e[R]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePaul Loren Swiecicki, MD, University of Michigan, Ann Arbor, Michigan \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuestions and Answers\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:30 p.m. – 5:30 p.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cb\u003eResearch Feature and Networking Reception\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbr\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"microAccordianHeader active\"\u003eFriday, February 25, 2022\u003c\/div\u003e\n\u003cdiv class=\"micro_accbod\" id=\"microAccordianBody_ScheduleofEvents3\"\u003e\n\u003cdiv class=\"ben_tableStyles\"\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"25%\"\u003e7:00 a.m. – 5:30 p.m.\u003c\/td\u003e\n\u003ctd width=\"75%\"\u003e\u003cstrong\u003eRegistration Open\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:00 a.m. – 8:00 a.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cb\u003eContinental Breakfast\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:55 a.m. – 8:00 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cb\u003eDay Two Welcome\u003c\/b\u003e\u003cbr\u003eQuynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California \u003cb\u003e[R]\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:00 a.m. – 8:20 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cb\u003ePatient Perspective\u003c\/b\u003e\u003cbr\u003eSpeaker: Andy Pluemer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:20 a.m. – 9:40 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eHOT TOPIC: Early Oral Cavity\u003c\/strong\u003e\u003cbr\u003eModerator:\u003cb\u003e \u003c\/b\u003eMike Moore, MD, Indiana University of Medicine, Indianapolis \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eTumor Board\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntraoperative Margin Assessment\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMark Varvares, MD, FACS, Massachusetts General Hospital, Boston \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePathologist’s Perspective\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMargaret Brandwein-Weber, MD, Mount Sinai, New York \u003cstrong\u003e[Pathologist]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSentinel Node and Neck Dissection\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eStephen Lai, MD, PhD, FACS, MD Anderson Cancer Center, Houston \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNew Frontiers in Sx: Fluorescence Guided Sx\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eEben Rosenthal, MD, Vanderbilt University Medical Center, Nashville \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSurgical Reconstruction\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eKelly Malloy, MD, University of Michigan, Ann Arbor, Michigan \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:40 a.m. – 10:25 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eKeynote II: Towards Personalization of HPV Related Oropharyngeal Carcinoma\u003c\/strong\u003e\u003cbr\u003eModerator: Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California \u003cstrong\u003e[R]\u003c\/strong\u003e\u003cbr\u003eSpeaker: Nancy Lee, MD, FASTRO, Memorial Sloan Kettering Cancer Center, New York \u003cstrong\u003e[R]\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:25 a.m. – 10:50 a.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cb\u003eCoffee Break\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:50 a.m. – 12:20 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cb\u003ePlenary II\u003c\/b\u003e\u003cbr\u003eModerator: Alexander Pearson, MD, PhD, University of Chicago, Chicago [M]\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAn Artificial Intelligence Ultrasound Platform for Screening and Staging of Thyroid Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAnnie Chan, Massachusetts General Hospital, Harvard Medical School, Boston\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDevelopment of a Deep Learning-based Auto-segmentation of Organs at Risk for Head and Neck Radiotherapy Planning\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eJihye Koo, University of South Florida, Tampa, Florida\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSafety and Efficacy of RP1 + Nivolumab in Patients with Non-melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1\/2 Multi-cohort Clinical Trial\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eJiaxin Niu, Banner MD Anderson Cancer Center, Houston\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eA Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Combinations in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eHarrison Cash, University of Washington Medical Center, Seattle\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEfficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results from a Phase II Cohort\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMay Cho, MD, University of California, Irvine, CA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Carcinoma: Results from the Phase II LT-SABR Study\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDavid Sher, University of Texas Southwestern Medical Center, Dallas\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStandard but Not Equal: Disparities in Advanced Radiotherapy Techniques for Head and Neck Cancer in the United States\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eNeal McCall, Winship Cancer Institute of Emory University, Atlanta\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFocal Adhesion Kinase Drives Resistance to Therapy in HPV-Negative Head and Neck Squamous Cell Carcinoma in a P53-Dependent Manner\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003ePhillip Pifer, UPMC Hillman Cancer Center, Pittsburgh\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12:20 p.m. – 1:20 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eLunch in the Exhibit Hall\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eEarly-career and Trainee Networking Luncheon: Launching Your Successful Career\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHow to Get Your Paper Published\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eRenata Ferrarotto, MD, MD Anderson Cancer Center, Houston, Texas \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinding Personal\/Professional Balance\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eCherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSeeking Out and Maintaining Mentoring Relationships\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eZain Husain, MD, Sunnybrook Health Sciences Centre, Ontario, Canada \u003cstrong\u003e[Dermatologist]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1:20 p.m. – 2:35 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePanel: Thyroid\u003c\/strong\u003e\u003cbr\u003eModerator: Sue Yom, MD, PhD, FASTRO, University of California, San Francisco \u003cstrong\u003e[R]\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMutational Landscape of Thyroid Cancers\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eNabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta \u003cb\u003e[M]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLow Risk Thyroid Cancer\u003c\/strong\u003e\/\u003cstrong\u003eRAI\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eJennifer Sipos, MD, The Ohio State University, Columbus, Ohio \u003cstrong\u003e[Endocrinologist]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTherapies for High Risk and Anaplastic Thyroid Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eSaad Khan, MD, Stanford University, Stanford, California \u003cb\u003e[M]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMultimodality Therapy for Aggressive Differentiated Thyroid Cancers\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMark Zafereo, MD, FACS, MD Anderson Cancer Center, Houston \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2:35 p.m. – 3:00 p.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCoffee Break\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:00 p.m. – 4:30 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eHOT Topic: Options in Advanced Skin Squamous Cell Carcinoma\u003c\/strong\u003e\u003cbr\u003eModerator: Robert Ferris, MD, PhD, University of Pittsburgh \u003cstrong\u003e[R]\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eControversies in Surgical Management\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eCecelia Schmalbach, MD, MSc, FACS, Temple Health, Philadelphia \u003cb\u003e[HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRole of Radiation\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e​Shlomo Koyfman, MD, Cleveland Clinic, Cleveland \u003cstrong\u003e[R]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSystemic Therapy\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eJessica Geiger, MD, Cleveland Clinic Cancer Center, Cleveland \u003cstrong\u003e[M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunotherapy in Special Populations\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAnne Chang, MD, Stanford University, Stanford, California \u003cb\u003e[Dermatologist]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuestions and Answers\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:30 p.m. – 5:30 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDevelopment of Survivorship Programs\u003c\/strong\u003e\u003cbr\u003eModerator: Jon Irish, MD, MSc, FRCSC, FACS, University of Toronto, Toronto, Ontario,Canada \u003cstrong\u003e[HNS]\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDeveloping Care Pathways\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eLiza Blumenfeld, MA, CCC-SLP, BCS-S, University of California, San Diego \u003cstrong\u003e[SLP]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePractice and Research\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMarci Lee Nilsen, PhD, RN, University of Pittsburgh, Pittsburgh \u003cstrong\u003e[RN]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Toxicity\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eJonas de Souza, MD, MBA, HCA Healthcare, Nashville \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuestions and Answers\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbr\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"microAccordianHeader active\"\u003eSaturday, February 26, 2022\u003c\/div\u003e\n\u003cdiv class=\"micro_accbod\" id=\"microAccordianBody_ScheduleofEvents4\"\u003e\n\u003cdiv class=\"ben_tableStyles\"\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"25%\"\u003e7:00 a.m. – 12:15 p.m.\u003c\/td\u003e\n\u003ctd width=\"75%\"\u003e\u003cstrong\u003eRegistration Open\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:00 a.m. – 8:00 a.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eContinental Breakfast\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:55 a.m. – 8:00 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDay Three Welcome\u003c\/strong\u003e\u003cbr\u003eFaye Johnson, MD, PhD, MD Anderson Cancer Center, Houston \u003cb\u003e[M]\u003c\/b\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:00 a.m. – 8:20 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePatient Perspective\u003c\/strong\u003e\u003cbr\u003eDavid Burkett\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:20 a.m. – 9:45 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDe-escalation for HPV\u003c\/strong\u003e\u003cbr\u003eModerator: Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston, \u003cstrong\u003e[SLP]\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntroduction\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eKatherine Hutcheson, PhD, MD Anderson Cancer Center, Houston \u003cstrong\u003e[SLP]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSurgical Considerations\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eUmamaheswar Duvvuri, MD, PhD, University of Pittsburgh, Pittsburgh\u003cb\u003e [HNS]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRadiation Considerations\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eBhisham Chera, MD, UNC School of Medicine, Chapel Hill, North Carolina \u003cb\u003e[R]\u003c\/b\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSystemic Considerations\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eNeil Hayes, MD, The University of Tennessee Health Science Center, Memphis, Tennessee \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuestions and Answers\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:45 a.m. – 10:30 a.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cb\u003eSalivary \u003c\/b\u003e\u003cstrong\u003eCancers\u003c\/strong\u003e\u003cbr\u003eModerator: Assuntina Gesualda Sacco, MD, University of California, San Diego, Moores Cancer Center, La Jolla, California \u003cb\u003e[M]\u003c\/b\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCurrent Approaches to Managing Salivary Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eKiran Kakarala, MD, University of Kansas Medical Center, Kansas City, Kansas\u003cstrong\u003e [HNS]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNovel Systemic Treatment for Recurrent or Metastatic Salivary Cancers\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eRenata Ferrarotto, MD, MD Anderson Cancer Center, Houston \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQuestions and Answers\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:30 a.m. – 10:45 a.m.\u003c\/td\u003e\n\u003ctd\u003e\u003cb\u003eCoffee Break\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:45 a.m. – 12:15 p.m.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cb\u003eRecurrent and Metastatic\u003c\/b\u003e\u003cstrong\u003e Head and Neck Cancer\u003c\/strong\u003e\u003cbr\u003eModerator: Farzan Siddiqui, MD, PhD, Henry Ford Cancer Institute, Detroit \u003cstrong\u003e[R]\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRe-irradiation for Recurrent and Second Primary Head and Neck Cancers\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eNeal Dunlap, MD, University of Louisville, Louisville, Kentucky \u003cb\u003e[R]\u003c\/b\u003e ​\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSurgical Salvage with Reconstruction\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eUrjeet Patel, MD, Northwestern Hospital, Chicago \u003cstrong\u003e[HNS]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNovel Targeted and Immunotherapies\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eChristine Chung, MD, Moffitt Cancer Center, Tampa, Florida \u003cstrong\u003e[M]\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCase Discussions\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbr\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954362093666,"sku":"MED-AMB01967","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Multidisciplinary-Head-and-Neck-Cancers-Symposium-2022.png?v=1779374679","url":"https:\/\/meducourse.com\/products\/multidisciplinary-head-and-neck-cancers-symposium-2022","provider":"Meducourse","version":"1.0","type":"link"}